Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: A randomized, controlled trial

Annals of Internal Medicine

Volumn 126, Issue 4, 1997, Pages 257-263

  Lalezari, Jacob P ^a   Stagg, Robert J ^b   Kuppermann, Baruch D ^c   Holland, Gary N ^d   Kramer, Françoise ^e   Ives, David V ^f   Youle, Michael ^g   Robinson, Michael R ^h   Drew, W Lawrence ⁱ   Jaffe, Howard S ^b  

^a Quest Clinical Research   (United States)

^b GILEAD SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JULES STEIN EYE INSTITUTE   (United States)

^e LAC USC MEDICAL CENTER   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g Kobler Centre   (United Kingdom)

^h Rochester Eye Center   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; PROBENECID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MORTALITY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RETINITIS; TREATMENT OUTCOME;

EID: 0031051578     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-4-199702150-00001     Document Type: Article

References (31)

1. Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med. 1993;329:1922-6.
2. Kuppermann BD, Petty JG, Richman DD, Mathews WC, Fullerton SC, Rickman LS, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy In patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115:575-82.
3. Holland GN, Repose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY. Acquired immune deficiency syndrome. Ocular manifestations. Ophthalmology. 1983;90:859-73.
4. Repose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY. Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology. 1985;92:472-84.
5. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989;107:75-80.
6. Spector SA, Weingeist T, Pollard RB, Dieterich DT, Samo T, Benson CA, et al. A randomized, controlled trial of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis. 1993;168: 557-63.
7. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4: Visual outcomes. Studies of the Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology. 1994;101:1250-61.
8. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of the Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N Engl J Med. 1992;326:213-20.
9. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of the Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Arch Intern Med. 1995;155:65-74.
10. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. The Oral Ganciclovir European and Australian Cooperative Study Group. AIDS. 1995;9:471-7.
11. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1995;333:615-20.
12. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res. 1987;8:261-72.
13. Snoeck R, Sakuma T, De Clercq E, Rosenberg I, Holy A. (S)-1-[3-hydroxy-2-(phosphonylmethoxypropyl)cytosine: a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 1988;32: 1839-44.
14. Bronson JJ, Ghazzouli I, Hitchcock MJ, Webb RR 2d, Martin JC. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. J Med Chem. 1989;32:1457-63.
15. Snoeck R, Andrei G, De Clercq E, Gerard M, Clumeck N, Tricot G, et al. A new topical treatment for resistant herpes simplex infections [Letter]. N Engl J Med. 1993;329:968-9.
16. Lalezari JP, Drew WL, Glutzer E, Miner D, Safrin S, Owen WF Jr, et al. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine of acydovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis. 1994;170:570-2.
17. Biron KK, Stanet SC, Sorrell JB, Fyfe JA, Keller PM, Lambe CU, et al. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]-methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci USA. 1985;82:2473-7.
18. Ho HT, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJ. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol. 1991;41:197-202.
19. Lalezarl JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis. 1995; 171:788-96.
20. Polis MA, Spooner KM, Baird BF, Manischewitz J, Jaffe HS, Fisher PE, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother. 1995;39:882-6.
21. Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Arch Ophthalmol, 1989;107:1759-66.
22. Karnofsky DA, Abelmann NH, Graver CF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;1: 634-56.
23. Meinert CL. Clinical Trials: Design, Conduct, and Analysis. New York: Oxford Univ Pr; 1986:198-9.
24. Kornhauser DM, Petty BG, Hendrix CW, Woods AS, Nerhood U, Bartlett JG, et al. Probenecid and zidovudine metabolism. Lancet. 1989;2:473-5.
25. Turner RR, Boone DC, Levine AM, Nichols PW, Parker JW. Flow cytometric lymphocyte immunophenotyping in homosexual men with the persistent generalized lymphadenopathy syndrome: a longitudinal study of lymph nodes and blood. Diag Clin Immunol. 1987;5:194-200.
26. Altman DG. Practical Statistics for Medical Research, London: Chapman and Hall; 1991.
27. O'Brien PC, Fleming TR. A paired Prentice-Wilcoxon test for censored paired data. Biometrics. 1987;43:169-80.
28. Martin DF, Parks DJ, Mellow SD, Ferris FL. Walton RC, Remaley NA, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol. 1994;112:1531-9.
29. Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 1981;6:135-51.
30. Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother, 1995;39:1247-52.
31. Palestine AG, Polis MA, De Smet MD, Baird BF, Fallon J, Kovacs JA, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991;115:665-73.